This is a prospective clinical study comparing two-stage breast reconstruction following mastectomy with and without the use of SurgiMend® PRS fetal bovine collagen matrix in patients with pre-mastectomy radiation therapy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
Capsular Contracture Rate
Capsular Contracture Rate (Baker III/IV): Reduction from control through 12 months after expander-to-permanent implant exchange
Time frame: 12 months Post-Exchange
Breast Q
No decrease in overall patient satisfaction from control as measured by the BREAST-Q Reconstruction Module Patient Satisfaction with Breasts survey, all questions a-p. Increase in patient satisfaction from control as measured by the BREAST-Q Reconstruction Module Patient Satisfaction with Breasts survey, questions related to capsular contracture.
Time frame: 12 months Post-Exchange
No. Capsule Procedures
Number of capsule procedures performed
Time frame: 12 months Post-Exchange
Cosmetic Assessment
Patient: (BREAST-Q Reconstruction Module) Surgeon: (panel review of standard photographs)
Time frame: 12 months Post-Exchange
Time to Completion
Time to Completion (expand-to-implant exchange)
Time frame: 12 months Post-Exchange
Total number of OR procedures
Procedural Attributes: Total number of OR procedures
Time frame: 12 month follow-up visit
Total number of visits
Procedural Attributes: Total number of ("in office" and OR procedures)
Time frame: 12 month follow up visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.